论文部分内容阅读
目的:评价新药甲磺酸加替沙星氯化钠注射液治疗下呼吸道细菌感染性疾病的疗效和安全性。方法:以加替沙星注射液为对照药,用随机双盲对照实验研究。结果:甲磺酸加替沙星氯化钠注射液组治疗下呼吸道感染的临床痊愈率与总有效率分别为72．5％及90％,与对照组分别为63．2％及81．6％相比,有统计学差异。不良反应发生率为7．5％ vs 10．5％,差异无统计学意义。结论:甲磺酸加替沙星氯化钠注射液治疗下呼吸道感染临床疗效较好,不良反应发生率较低。
Objective: To evaluate the efficacy and safety of the new drug gatifloxacin sodium chloride injection in the treatment of bacterial infections of lower respiratory tract. Methods: Gatifloxacin injection as a control drug, a randomized double-blind controlled experimental study. Results: The clinical cure rate and total effective rate of Gatifloxacin and sodium chloride injection in the treatment of lower respiratory tract infection were 72.5% and 90% respectively, which were 63.2% and 81.6% respectively compared with the control group % Compared to a statistically significant difference. The incidence of adverse reactions was 7.5% vs 10.5%, the difference was not statistically significant. Conclusion: Gatifloxacin mesylate sodium chloride injection in the treatment of lower respiratory tract infection has a good clinical effect, the incidence of adverse reactions is low.